Mount Sinai Study Links PFAS Exposure to Childhood Gut Inflammation Across 3 Cohorts
Updated
Updated · Mount Sinai · Jul 16
Mount Sinai Study Links PFAS Exposure to Childhood Gut Inflammation Across 3 Cohorts
2 articles · Updated · Mount Sinai · Jul 16
Summary
Children exposed to higher PFAS levels before birth and early in life showed higher fecal calprotectin years later, linking "forever chemicals" to intestinal inflammation in a first-of-its-kind study.
Three birth cohorts in the United States and Mexico were followed for up to 11 years after researchers measured PFAS in maternal blood, umbilical cord blood and newborn dried blood spots.
Both legacy PFAS and newer replacement compounds tracked with higher inflammation markers, and researchers said analyzing PFAS as mixtures better reflected real-world exposure.
The study was observational, so it did not prove PFAS cause inflammation or inflammatory bowel disease, but it suggests early-life exposure could shape later gut health and future IBD risk.
Could prenatal exposure to both old and replacement PFAS be quietly inflaming children’s guts years before any IBD symptoms appear?
If PFAS mixtures in pregnancy predict higher childhood gut inflammation, which everyday exposure sources should families worry about most?
Early-Life PFAS Exposure and Childhood Gut Inflammation: The 2026 Mount Sinai Study, Health Risks, and Policy Responses
Overview
The July 2026 Mount Sinai study reveals that when pregnant mothers and young children are exposed to PFAS, these chemicals can disrupt the gut’s protective barrier by down-regulating key proteins, leading to increased intestinal permeability and inflammation. This chronic inflammation, detected by elevated fecal calprotectin, raises the risk of developing inflammatory bowel diseases like Crohn’s or ulcerative colitis later in life. Because PFAS accumulate in the body over decades due to widespread exposure from water, food packaging, and household products, effective interventions—such as certified water filters and medical treatments like bile acid sequestrants—are essential to reduce PFAS levels and protect vulnerable populations.